The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma.

The firm will focus on programs for MYBPC3-associated hypertrophic cardiomyopathy and PKP2-associated arrhythmogenic right ventricular cardiomyopathy.

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

Researchers shared data at ACC from BioCardia's initial Phase III cell therapy trial, which the firm stopped enrolling based ...

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...

Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

HHS had argued that Vertex's plan to cover fertility services for some patients that took its gene therapy would violate anti-kickback and inducement laws.

NEW YORK – The National Comprehensive Cancer Network has taken a more favorable stance on DPYD pharmacogenetic testing in recently updated colon, anal, rectal, and small bowel cancer treatment ...

Researchers at ACC's annual meeting reported first-in-human data from a clinical trial of TN-201 that suggested symptom improvement.

Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.